Federal contract award
75A50123C00022
ADVANCE THE DEVELOPMENT OF TWO ANTIBIOTICS FOR USE IN THE PEDIATRIC POPULATION FOR THE TREATMENT OF SERIOUS BACTERIAL INFECTIONS WHERE MULTIDRUG-RESISTANT ORGANISMS ARE COMMON, AND 2) DEVELOP ANTIBIOTICS FOR USE IN PUBLIC HEALTH AND BIOTHREAT EMERGEN
Award details
Obligations, current value and potential value describe different measures; they are never added together.
| Field | Reported value |
|---|---|
| Agency | Department of Health and Human Services |
| Office | BARDA - ASPR / DAAPPO / BARDA DCMA |
| NAICS | 541714 — Research and Development in Biotechnology (except Nanobiotechnology) |
| PSC | AN44 — HEALTH R&D SERVICES; HEALTH CARE - OTHER; R&D ADMINISTRATIVE EXPENSES |
| Parent award / vehicle | Not reported |
| Set-aside | NO SET ASIDE USED. |
| Pricing type | COST SHARING |
| Obligations | $47.5M |
| Current contract value | $47.5M |
| Potential contract value / ceiling | $164.3M |
| Start date | Jul 6, 2023 |
| Current end date | Jun 30, 2030 |
| Potential end date | Aug 6, 2034 |
| Latest award activity | Sep 25, 2025 |
| Source loaded | Sep 26, 2026 |
Funding and modification history
Showing the latest 6 of 6 loaded transactions. Negative values are deobligations.
| Date | Modification | Obligation change | Description |
|---|---|---|---|
| Sep 25, 2025 | P00005 | $8.6M | THE PURPOSE OF THIS MODIFICATION IS TO IS EXERCISE AND FULLY FUND CLIN0002/OPTION 1 |
| Sep 12, 2025 | P00004 | $12.8M | THE PURPOSE OF THIS MODIFICATION IS TO IS EXERCISE AND FULLY FUND OPTION 5/CLIN0004, PROVIDE SUPPLEMENTAL FUNDING FOR CLIN0001 AND CLIN0003, REVISE THE BUDGET AND PERIOD OF PERFORMANCE FOR CLIN0006, AND UPDATE THE STATEMENT OF WORK. |
| Mar 28, 2025 | P00003 | $0 | NO COST EXTENSION FOR CLIN 0003, UPDATE KEY PERSONNEL, ADD ALTERNATE COR, ADDS/REMOVES CLAUSES BASED ON EXECUTIVE ORDERS |
| Sep 5, 2024 | P00002 | $4.6M | EXERCISE CLIN 0004 OPTION |
| May 13, 2024 | P00001 | $1.0M | ADVANCE THE DEVELOPMENT OF TWO ANTIBIOTICS FOR USE IN THE PEDIATRIC POPULATION FOR THE TREATMENT OF SERIOUS BACTERIAL INFECTIONS WHERE MULTIDRUG-RESISTANT ORGANISMS ARE COMMON, AND 2) DEVELOP ANTIBIOTICS FOR USE IN PUBLIC HEALTH AND BIOTHREAT EMERGEN |
| Jul 6, 2023 | 0 | $20.5M | ADVANCE THE DEVELOPMENT OF TWO ANTIBIOTICS FOR USE IN THE PEDIATRIC POPULATION FOR THE TREATMENT OF SERIOUS BACTERIAL INFECTIONS WHERE MULTIDRUG-RESISTANT ORGANISMS ARE COMMON, AND 2) DEVELOP ANTIBIOTICS FOR USE IN PUBLIC HEALTH AND BIOTHREAT EMERGEN |
Estimated positioning window
Aug 6, 2033 – Feb 6, 2034
30/100
Why this recompete signal
Contract timing and recorded acquisition signals at the time of calculation.
Stored score: 30/100. Available recorded signals: 25 points.
- Contract end 2034-08-06 (2842 days from calculation)
- +5 points
- 2 historical awards in this buyer and category group
- +10 points
- 6 recorded award transactions
- +10 points
- Latest award action: 2025-09-25
- +0 points
- Parent award identifier recorded
- +0 points
- Solicitation identifier recorded
- +0 points
- Linked official forecast
- +0 points
- Calculated on
- 2026-10-25 10:18:04.631876+00:00
The historical group combines buyer, NAICS, and PSC. Multiple awards in this group do not by themselves establish repeated competitions.
Rule-based research score; it does not measure your chance of winning.
This older calculation does not retain a complete reproducible breakdown. Missing or changed inputs are not assigned invented points: Original award-value bonus input.
Recompete score calculated Oct 25, 2026.
Research next steps
- Check the linked forecast or SAM for a confirmed solicitation and current timing.
- Verify whether remaining options may extend performance beyond the current end date.
- Check the stated set-aside against the solicitation and current certifications.
- Review the award scope and buyer evidence before making a bid/no-bid decision.